Hackers claim millions of patient records stolen during data breach at healthcare giant McKesson
The company, which distributes medicines and medical devices to hospitals and healthcare practices across the U.S., said it was hacked and expects intermittent service degradation.
What it means
- What to watch: Approvals and strong trial data can reprice a drugmaker quickly — especially when one product is most of the company.
- How the stock is trading: $MCK -0.80% in the latest session.
- Timing: It dropped mid-session, while New York was open, so the move beside it may already include the market's first reaction.
Where the stock stands
$MCK last changed hands at $959.27, -0.80% on the session, 6.9% below its 52-week high of $1,030.27 and 33% above its low of $723.68 — in the upper part of the range. Over the year it has ranged 42% from low to high: a moderate band — lively, not wild. These are latest-session quotes, not live prices — the live tape is on the $MCK page.
How much coverage it is getting
In the last 30 days Wook has filed 2 stories about $MCK — 0 of them this week. None arrived this week, so the run has gone quiet. Across those stories 1 read bullish, 1 neutral and 0 bearish. This one reads bullish, so it sits in step with most of the run. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$MCK earnings in 7 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
The $MCK page has the full chart, the filings and the valuation model behind every figure here. Comparing how two or three outlets frame the same story is the fastest way to separate the facts from the angle. Wook AI, above, can pull live figures and run the numbers on request — how far $MCK is from its high, or how this week's coverage compares.
How this analysis was made
TechCrunch published it, and Wook filed it under Healthcare & Pharma. It reads bullish at medium severity because of “record” in the wording, with nothing on the bearish side to offset it. It was matched to $MCK. The preview above is the publisher's own wording.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
TechCrunch published this on August 31, 2026. $MCK has moved +5.79% ($906.77 to $959.26). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.